Molecular therapies in hepatocellular carcinoma: What can we target?

Roberto Galuppo, Dinesh Ramaiah, Oscar Moreno Ponte, Roberto Gedaly

Research output: Contribution to journalReview articlepeer-review

42 Scopus citations


Numerous signaling pathways, such as Ras/Raf/MAPK, have been implicated in hepatic carcinogenesis. There are at least 35 combination therapy studies for advanced stage hepatocellular carcinoma (HCC) ongoing, and numerous reagents are being tested targeting novel signaling cascades. The management of HCC has changed substantially in recent times, and the successful development of sorafenib has prompted further expansion on molecular targeted therapies to potentially inhibit different pathways in hepatocarcinogenesis.

Original languageEnglish (US)
Pages (from-to)1688-1697
Number of pages10
JournalDigestive Diseases and Sciences
Issue number8
StatePublished - Aug 2014


  • Epidermal growth factor
  • Hepatocellular carcinoma
  • Liver cancer stem cells
  • Ras/Raf/MAPK
  • Sorafenib

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology


Dive into the research topics of 'Molecular therapies in hepatocellular carcinoma: What can we target?'. Together they form a unique fingerprint.

Cite this